Evidence map›Paper›PMID 21207250›Full record

Trial reportLipids2011

Simvastatin therapy reduces prooxidant-antioxidant balance: results of a placebo-controlled cross-over trial.

Seyyed M R Parizadeh, Mahmoud R Azarpazhooh, Mohsen Moohebati, Mohsen Nematy, Majid Ghayour-Mobarhan, Shima Tavallaie, Amir A Rahsepar, Maral Amini, Amirhossein Sahebkar, Maryam Mohammadi and 1 more

Open access · bronzeAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Lipids, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
89citing papers in PubMed, 11 pooled it
3.2field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

89 citing papers in PubMed, 11 syntheses or guidelines pooled it, 177 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Effect of ezetimibe on plasma adipokines: a systematic review and meta-analysis.British journal of clinical pharmacology · 2017 · on this map
    Pooled it
  10. Pooled it
  11. Pooled it
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article

29 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Seyyed M R ParizadehDepartment of Biochemistry and Nutrition, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Mahmoud R Azarpazhooh
Mohsen Moohebati
Mohsen Nematy
Majid Ghayour-Mobarhan
Shima Tavallaie
Amir A Rahsepar
Maral Amini
Amirhossein Sahebkar
Maryam Mohammadi
Gordon A A Ferns
Mashhad University of Medical Sciences · IRIslamic Azad University, Mashhad · IRKeele University · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oxidative stress is thought to play an important role in atherogenesis. The statin group of cholesterol-lowering drugs have been shown to reduce cardiovascular events and possess antioxidant properties. We aimed to assess the effects of simvastatin on a novel measure of prooxidant-antioxidant balance (PAB) in dyslipidemic patients. The PAB assay can measure the prooxidant burden and the antioxidant capacity simultaneously in one assay, thereby giving a redox index. We treated 102 dyslipidemic individuals with simvastatin, or a placebo in a double-blind, cross-over, placebo-controlled trial. PAB values were measured before and after each treatment period. Seventy-seven subjects completed the study. We found that statin therapy was associated with a significant reduction in PAB values (P < 0.001). This effect appeared to be independent of the cholesterol-lowering effects of statins. We conclude that serum PAB values are decreased by simvastatin therapy. Regarding previous reports on the elevation of PAB in conditions associated with oxidative stress, the PAB assay, along with other markers of oxidative stress, may be applied to estimate the extent of oxidative stress in patients, assessment of the antioxidative efficacy of medication such as statins and perhaps also for the identification of those individuals who need antioxidant therapy.

Indexed as

Anticholesteremic AgentsPlacebosSimvastatinAdultAgedAged, 80 and overAntioxidantsCross-Over StudiesDouble-Blind MethodDyslipidemiasFemaleHumansMaleMiddle AgedOxidative StressReactive Oxygen SpeciesAnticholesteremic AgentsAntioxidantsPlacebosReactive Oxygen SpeciesSimvastatin

Identifiers

PMID21207250
OpenAlexW2025039190

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.